Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 25,598 | 23,555 | 25,660 | 20,362 | 17,966 |
| TOTAL | $27,287 | $25,460 | $27,710 | $21,611 | $19,468 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 368 | 430 | 490 | 552 | 613 |
| TOTAL | $368 | $430 | $490 | $552 | $613 |
| Total Assets | $27,655 | $25,890 | $28,200 | $22,163 | $20,081 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,698 | 3,797 | 6,431 | 2,681 | 1,976 |
| Accrued Expenses | 10,856 | 8,836 | 9,182 | 7,841 | 7,913 |
| TOTAL | $14,617 | $12,633 | $15,676 | $10,522 | $9,953 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 95,185 | 84,343 | 72,765 | 62,514 | 61,255 |
| TOTAL | $95,185 | $84,343 | $72,765 | $62,514 | $61,255 |
| Total Liabilities | $109,802 | $96,976 | $88,441 | $73,036 | $71,208 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 62,278 | 62,148 | 61,904 | 61,849 | 59,582 |
| Common Shares | 62 | 61 | 61 | 61 | 59 |
| Retained earnings | -378,304 | -365,869 | -354,372 | -344,312 | -330,271 |
| Other shareholders' equity | 2,223 | 2,223 | 2,223 | 2,233 | 2,233 |
| TOTAL | $-82,147 | $-71,086 | $-60,241 | $-50,873 | $-51,127 |
| Total Liabilities And Equity | $27,655 | $25,890 | $28,200 | $22,163 | $20,081 |